Anti-VEGF antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same
US9822174B2 · kind B2 · utility
2Cited by
2References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 30, 2014 |
| Grant date | Nov 21, 2017 |
| Priority date | — |
| Expiry date | Aug 14, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel anti-vascular endothelial growth factor (VEGF) antibody having a strong binding affinity for VEGF and capable of inhibiting in vivo tumor growth and a composition for the treatment of cancer, containing the same. The antibody shows a remarkable binding property to human and mouse VEGF, suppresses the proliferation and permeability of a human umbilical vein endothelial cell (HUVEC) and inhibits tumor growth, and thus can be useful as an antibody for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.